- Home
- ACRS vs BRAG Comparison
ACRS vs BRAG Comparison
Compare ACRS & BRAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- BRAG
- Stock Information
- Founded
- ACRS 2012
- BRAG 2018
- Country
- ACRS United States
- BRAG Canada
- Employees
- ACRS N/A
- BRAG N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- BRAG Office Equipment/Supplies/Services
- Sector
- ACRS Health Care
- BRAG Technology
- Exchange
- ACRS Nasdaq
- BRAG Nasdaq
- Market Cap
- ACRS 132.0M
- BRAG 138.8M
- IPO Year
- ACRS 2015
- BRAG N/A
- Fundamental
- Price
- ACRS $2.24
- BRAG $5.44
- Analyst Decision
- ACRS Strong Buy
- BRAG Strong Buy
- Analyst Count
- ACRS 5
- BRAG 4
- Target Price
- ACRS $11.00
- BRAG $7.75
- AVG Volume (30 Days)
- ACRS 656.6K
- BRAG 89.6K
- Earning Date
- ACRS 03-04-2025
- BRAG 03-25-2025
- Dividend Yield
- ACRS N/A
- BRAG N/A
- EPS Growth
- ACRS N/A
- BRAG N/A
- EPS
- ACRS N/A
- BRAG N/A
- Revenue
- ACRS $27,079,000.00
- BRAG $109,522,641.00
- Revenue This Year
- ACRS N/A
- BRAG $11.40
- Revenue Next Year
- ACRS N/A
- BRAG $10.75
- P/E Ratio
- ACRS N/A
- BRAG N/A
- Revenue Growth
- ACRS 26.35
- BRAG 4.64
- 52 Week Low
- ACRS $0.95
- BRAG $2.86
- 52 Week High
- ACRS $5.17
- BRAG $7.00
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- BRAG 59.49
- Support Level
- ACRS $2.11
- BRAG $5.11
- Resistance Level
- ACRS $2.42
- BRAG $6.12
- Average True Range (ATR)
- ACRS 0.15
- BRAG 0.33
- MACD
- ACRS 0.00
- BRAG -0.04
- Stochastic Oscillator
- ACRS 26.53
- BRAG 52.05
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.